Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor–Induced Upper Airway Angioedema Richard Sinert, DO, Phillip Levy, MD, MPH,

Slides:

Advertisements

Similar presentations

Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria Matt Morgan, MD, Andrew Cooke, MD, Laura Rogers,

Advertisements

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

The Relationship Between a Specific IgE Level and Asthma Outcomes: Results from the National Health and Nutrition Examination Survey Whitney.

Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks Timothy J. Craig, MD, Robyn J. Levy,

Mental Health Services Claims and Adult Onset Asthma in Ontario, Canada Teresa To, PhD, Kandace Ryckman, MPH, Jingqin Zhu, MSc, Devon Williams, MSc, Laura.

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study Eli O. Meltzer, MD, Paul.

David McD. Taylor, MD, MPH, Celene Y. L. Yap, MSc, Jonathan C

Aleena Banerji, MD, Kimberly G. Blumenthal, MD, MSc, Kenneth H

Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy Thomas B. Casale, MD, Jonathan A. Bernstein,

Vitamin D Insufficiency and Asthma in a US Nationwide Study

Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in Adolescents James W. Baker, MD, Avner Reshef, MD, Dumitru Moldovan,

Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks Timothy J. Craig, MD, Robyn J. Levy,

Primary Prevention of Food Allergy: Translating Evidence from Clinical Trials to Population-Based Recommendations Paul J. Turner, FRACP, PhD, Dianne.

Complementary and Alternative Medicine in Allergy-Immunology: More Information is Needed Leonard Bielory, MD The Journal of Allergy and Clinical Immunology:

Wells Syndrome with Bullous Lesions

Dennis K. Ledford, MD, Sally Wenzel, MD

James L. Friedlander, MD, William J. Sheehan, MD, Sachin N

Desensitization to Chemotherapeutic Agents

Intramuscular Versus Intravenous Immunoglobulin Replacement Therapy and Measurement of Immunoglobulin Levels During Immunoglobulin Replacement Therapy

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Marcus Shaker, MD, MS, Tsuzumi Kanaoka, BA, Robert G. P

Practice Notes from the AAAI

An Infant with Atopic Dermatitis and Itching After Ingestion of Milk

David McD. Taylor, MD, MPH, Celene Y. L. Yap, MSc, Jonathan C

Comparative Effectiveness of Budesonide-Formoterol Combination and Fluticasone- Salmeterol Combination for Asthma Management: A United States Retrospective.

Safety of Fluticasone Propionate Prescribed for Asthma During Pregnancy: A UK Population-Based Cohort Study Rachel A. Charlton, PhD, Julia M. Snowball,

Comparative Analysis of Persistence to Treatment among Patients with Asthma or COPD Receiving AirFluSal Forspiro or Seretide Diskus Salmeterol/Fluticasone.

The Cost of Self-Reported Penicillin Allergy: A Systematic Review

Reactions to Rituximab in an Outpatient Infusion Center: A 5-Year Review Amy S. Levin, MD, Iris M. Otani, MD, Timothy Lax, MD, Ephraim Hochberg, MD, Aleena.

Validation of the Pregnancy Asthma Control Test

Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies Jolan E. Walter, MD, PhD, Jocelyn.

The Relationship Between a Specific IgE Level and Asthma Outcomes: Results from the National Health and Nutrition Examination Survey Whitney.

Timothy J. Craig, DO, H. Henry Li, MD, Marc Riedl, MD, Jonathan A

A focused parameter update: Hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor–associated angioedema

Treatment of chronic autoimmune urticaria with omalizumab

Nonadherence to Asthma Treatment: Getting Unstuck

Impact of Adverse Event Solicitation on the Safety Profile of SQ House Dust Mite Sublingual Immunotherapy Tablet Hendrik Nolte, MD, PhD, David I. Bernstein,

Successful treatment of idiopathic angioedema with ecallantide

Practice Notes from the AAAAI

Aimee L. Speck, MD, Michael Hess, MSI, Alan P. Baptist, MD, MPH

Management of Difficult-to-Treat Atopic Dermatitis

Necdet B. Gunsoy, PhD, Sarah M. Cockle, PhD, Steven W

Fatal Anaphylaxis: Mortality Rate and Risk Factors

Repeated Episodes of Anaphylaxis with Normal Serum Tryptase but Elevated Levels of Urinary Prostaglandin D2 Phillip Lieberman, MD The Journal of Allergy.

Penicillin Skin Testing Is a Safe and Effective Tool for Evaluating Penicillin Allergy in the Pediatric Population Stephanie J. Fox, MD, Miguel A. Park,

Phillip Lieberman, MD, Michael Tankersley, MD

The Emperor Has No Symptoms: The Risks of a Blanket Approach to Using Epinephrine Autoinjectors for All Allergic Reactions Paul J. Turner, FRACP, PhD,

News & Notes Journal of Allergy and Clinical Immunology

Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria Matt Morgan, MD, Andrew Cooke, MD, Laura Rogers,

The Management of Eosinophilic Esophagitis

Phillip Lieberman, MD, David Golden, MD

Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab–clinical characteristics and treatment Andreas Wollenberg, MD, PhD, Lieneke.

Sequential Treatment Initiation with Timothy Grass and Ragweed Sublingual Immunotherapy Tablets Followed by Simultaneous Treatment Is Well Tolerated

Comparison of asthma prevalence among African American teenage youth attending public high schools in rural Georgia and urban Detroit Dennis R. Ownby,

Neetu Talreja, MD, Richard F. Lockey, MD

Mapping the Asthma Care Process: Implications for Research and Practice Alexandra Lelia Dima, PhD, Marijn de Bruin, PhD, Eric Van Ganse, MD, PhD, FRCP

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

Sharon Seth, MD, David A. Khan, MD

Cephalosporin Side Chain Cross-reactivity

Trial Quality in Nephrology: How Are We Measuring Up?

News & Notes Journal of Allergy and Clinical Immunology

Impact of Adverse Event Solicitation on the Safety Profile of SQ House Dust Mite Sublingual Immunotherapy Tablet Hendrik Nolte, MD, PhD, David I. Bernstein,

Practice Notes from the AAAI

Clinical Management of Atopic Dermatitis: Practical Highlights and Updates from the Atopic Dermatitis Practice Parameter 2012 Peter A. Lio, MD, Margaret.

Footnotes1 Journal of Allergy and Clinical Immunology

Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor–Induced Upper Airway Angioedema Richard Sinert, DO, Phillip Levy, MD, MPH,

Budesonide Inhalation Suspension Versus Montelukast in Children Aged 2 to 4 Years with Mild Persistent Asthma Stanley J. Szefler, MD, Lars-Goran Carlsson,

Pedro Giavina-Bianchi, MD, PhD, Shih-Wen Huang, MD

Primary Prevention of Food Allergy: Translating Evidence from Clinical Trials to Population-Based Recommendations Paul J. Turner, FRACP, PhD, Dianne.

News & Notes Journal of Allergy and Clinical Immunology

Presentation transcript:

Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor–Induced Upper Airway Angioedema Richard Sinert, DO, Phillip Levy, MD, MPH, Jonathan A. Bernstein, MD, Richard Body, MB ChB, PhD, Marco L.A. Sivilotti, MD, MSc, Joseph Moellman, MD, Jennifer Schranz, MD, Jovanna Baptista, MS, Alan Kimura, MD, PhD, Wolfram Nothaft, MD The Journal of Allergy and Clinical Immunology: In Practice Volume 5, Issue 5, Pages 1402-1409.e3 (September 2017) DOI: 10.1016/j.jaip.2017.03.003 Copyright © 2017 The Authors Terms and Conditions

Figure 1 Flow diagram of subjects. The intention-to-treat population comprised all randomized subjects (N = 121). The modified intention-to-treat population comprised all randomized subjects who received the study drug (n = 118). The safety population comprised all subjects who received the study drug (n = 118). *Discharged from hospital approximately 13 hours after treatment having met discharge criteria, but could not be reached for the day 3 safety follow-up. The Journal of Allergy and Clinical Immunology: In Practice 2017 5, 1402-1409.e3DOI: (10.1016/j.jaip.2017.03.003) Copyright © 2017 The Authors Terms and Conditions

Figure 2 Kaplan-Meier plots. A, Time to meeting discharge criteria by treatment group. B, TOSR by treatment group (intention-to-treat population). Subjects who did not achieve the end point within the observation period were censored at the last observation time. One subject (icatibant group) who achieved the end points at 96 hours posttreatment was not plotted in this graph. The Journal of Allergy and Clinical Immunology: In Practice 2017 5, 1402-1409.e3DOI: (10.1016/j.jaip.2017.03.003) Copyright © 2017 The Authors Terms and Conditions